Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

US7851637B2 · kind B2 · utility

Assignee

• Infinity Pharmaceuticals, Inc. · US

Inventors

• Alfredo C. Castro · Woburn, US
• Wei Deng · Shanghai, CN
• Kristopher M. Depew · Acton, US
• Michael Foley · New York, US
• Christian Fritz · Natick, US
• Asimina T. Georges Evangelinos · Andover, US
• Michael J. Grogan · Winchester, US
• Nafeeza Hafeez · Brookline, US
• Edward Holson · Newton, US
• Brian T. Hopkins · Newton, US
• Nii O. Koney · New York, US
• Tao Liu · Shanghai, CN
• David A. Mann · Swampscott, US
• Lisa A. Marcaurelle · Boston, US
• Daniel A. Snyder · Somerville, US
• Dennis John Underwood · Brookline, US
• Andrew Alistair WYLIE · Newton, US
• Lin Yu · San Diego, US
• Linping Zhang · Lexington, US

Key dates

• Filing date: Jun 17, 2005
• Grant date: Dec 14, 2010
• Expiry date: Aug 2, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.